Eloralintide vs Retatrutide: Amylin vs Triple Agonist | telos rx
Healthy bowl of greens, eggs, tomatoes and avocado on a wooden table, illustrating nutrition alongside GLP-1 research
← Back to blog
amylin agonist

Eloralintide vs Retatrutide: Differences & Which to Watch

By TelosRX Editorial Team

Eloralintide vs retatrutide comes down to one pathway versus three. Eloralintide targets the amylin receptor alone, while retatrutide hits GIP, GLP-1 and glucagon receptors, and both are investigational. TelosRX explains what each trial found.

Two of the most searched obesity drugs right now aren't on pharmacy shelves yet. Both come from Eli Lilly and are weekly injections in trials. They work in very different ways.

Here's a clear, side-by-side look at what each molecule does, what the published data shows, and what you can actually get today.

What Is Eloralintide?

Eloralintide is an investigational selective amylin receptor agonist. That means it mimics amylin, a hormone your pancreas releases alongside insulin after you eat.

Amylin acts in the brainstem to boost fullness. It also slows how fast food leaves your stomach. Eloralintide is built to hit that one receptor cleanly, with once-weekly dosing in trials.

It is not FDA-approved. For the full background, see our eloralintide explainer.

What Is Retatrutide?

Retatrutide is an investigational triple hormone receptor agonist. One molecule activates three receptors: GIP, GLP-1 and glucagon.

GLP-1 and GIP are gut hormones that curb appetite and support insulin release after meals. Glucagon receptor activity is added because it may raise energy use and shift how the liver handles fat.

Retatrutide is also not FDA-approved. Lilly states it is legally available only to people enrolled in its clinical trials.

Eloralintide vs Retatrutide: Head-to-Head Comparison

This table pulls from the published Phase 2 trials and Lilly's reported Phase 3 topline data. No trial has compared the two drugs directly.

Feature Eloralintide Retatrutide
Developer Eli Lilly Eli Lilly
Drug class Selective amylin receptor agonist GIP, GLP-1 and glucagon triple agonist
Receptors targeted 1 (amylin) 3 (GIP, GLP-1, glucagon)
Main appetite effect Fullness signal from the brainstem; slower stomach emptying Appetite reduction plus possible rise in energy use
Dosing in trials Once weekly, doses up to 9 mg Once weekly, doses up to 12 mg
Furthest stage Phase 2 published; Phase 3 planned Phase 3 (TRIUMPH program)
Key published trial Phase 2, 263 adults, 48 weeks (The Lancet, 2025) Phase 2, 338 adults, 48 weeks (NEJM, 2023)
Mean weight reduction reported 9.5% to 20.1% across doses vs 0.4% placebo Up to 24.2% at 48 weeks (Phase 2); up to 28.7% at 68 weeks (TRIUMPH-4 topline)
Most common side effects Mild-to-moderate GI symptoms Dose-related GI symptoms; heart rate increase
FDA status Not FDA-approved Not FDA-approved
Available by prescription? No No

Mechanism: One Pathway vs Three

The cleanest way to frame this is precision versus breadth. Retatrutide pulls three levers at once. Eloralintide pulls one, as cleanly as it can.

  • Breadth (retatrutide): more signals can mean a higher ceiling for weight reduction. It also means more body systems are engaged.
  • Precision (eloralintide): one target may mean fewer side effects. The open question is how far a single pathway can go.

Amylin and GLP-1 work through different circuits. That's why Lilly is also testing eloralintide alongside tirzepatide, rather than only as a replacement.

What the Eloralintide Trial Showed

The Phase 2 trial enrolled 263 adults with obesity or overweight and at least one weight-related condition. People with type 2 diabetes were excluded. It ran 48 weeks.

Every dose arm beat placebo. Mean weight reduction ranged from 9.5% to 20.1%, versus 0.4% on placebo. The results were published in The Lancet in 2025.

Researchers also reported improvements in waist size, blood pressure, lipids and blood sugar markers. Those are secondary measures, so read them as early signals.

What the Retatrutide Trials Showed

The Phase 2 obesity trial enrolled 338 adults without type 2 diabetes. At 48 weeks, the highest dose produced a mean weight reduction of up to 24.2%. The data appeared in the New England Journal of Medicine.

In December 2025, Lilly reported topline Phase 3 results from TRIUMPH-4. That trial studied adults with obesity and knee osteoarthritis. The 12 mg dose showed a mean weight reduction of up to 28.7% at 68 weeks, along with lower knee pain scores.

Topline data is a company summary, not a peer-reviewed paper. Full publication will tell us more. You can track every registered study on ClinicalTrials.gov.

Side Effects Compared

Both drugs list stomach-related effects as the most common. The pattern differs a bit.

  • Eloralintide: GI symptoms were mostly mild to moderate. At lower doses, rates looked similar to placebo.
  • Retatrutide: nausea, diarrhea, vomiting and constipation rose with dose, mostly during dose increases. Heart rate also rose in a dose-related way.

Neither drug has long-term safety data yet. Our retatrutide side effects guide covers the trial details.

Why You Can't Rank Them on Trial Numbers

It's tempting to say 24% beats 20%. That's not a fair read. The numbers come from separate trials with different doses, timelines and populations.

Trial length alone moves results a lot. Retatrutide's own Phase 2 showed lower numbers at 24 weeks than at 48. Until a head-to-head trial exists, the comparison is directional only.

Combination Trials: Where Each Drug May End Up

The next chapter may be about pairing, not picking. Amylin and incretin drugs act on different circuits, so researchers are testing them together.

  • Eloralintide plus tirzepatide: Lilly calls this pairing eloraTZP. In a small Phase 1 study, Lilly reported more 16-week weight reduction with the pair than with tirzepatide alone.
  • CagriSema: Novo Nordisk pairs the amylin analog cagrilintide with semaglutide. It's the most advanced amylin-plus-GLP-1 combination.
  • Retatrutide: as a triple agonist, it already bundles three signals into one molecule. Most of its trials test it on its own.

No trial has paired eloralintide with retatrutide. Any claim about that stack is guesswork.

Is Eloralintide or Retatrutide Available Now?

No. Neither drug can be legally prescribed outside a clinical trial.

Products sold online as "Elora" or "Reta" are unapproved research chemicals. They're not made for human use, and their purity and sterility can't be verified.

Regulators have flagged counterfeit and unapproved versions of popular weight-loss drugs. If you want to try retatrutide, the legitimate route is a trial listed on ClinicalTrials.gov.

Which to Watch, and What You Can Use Today

Retatrutide currently holds the higher reported ceiling. Eloralintide's story is about tolerability. Both may matter, and they could end up paired with other drugs rather than competing.

If you want a GLP-1 option now, approved and compounded choices already exist. Compare GLP-1 options at TelosRX, including tirzepatide, a dual GIP and GLP-1 agonist. For the amylin side of the science, read our amylin vs GLP-1 comparison.

Any prescription is subject to medical approval by a licensed provider, and compounded tirzepatide is not FDA-approved. TelosRX works asynchronously: you complete an online health intake, and a licensed provider reviews it. No live video visit is required.

Frequently Asked Questions

Is eloralintide the same as retatrutide?

No. Eloralintide is a selective amylin receptor agonist. Retatrutide is a triple agonist that activates GIP, GLP-1 and glucagon receptors. Both are investigational Eli Lilly drugs given as weekly injections in trials, but they act on different biology and neither is FDA-approved.

Which caused more weight loss in trials, eloralintide or retatrutide?

Retatrutide's Phase 2 trial reported a mean reduction of up to 24.2% at 48 weeks. Eloralintide's Phase 2 trial reported 9.5% to 20.1% at 48 weeks. These were separate trials with different designs, so the numbers are not a direct ranking. No head-to-head study exists.

What is eloralintide?

Eloralintide is an investigational once-weekly injection from Eli Lilly that mimics amylin, a hormone released with insulin after meals. It is designed to act on the amylin receptor alone. It works by boosting fullness and slowing stomach emptying. It remains in clinical trials and is not FDA-approved.

How does retatrutide work compared to Ozempic?

Ozempic contains semaglutide, which activates one receptor: GLP-1. Retatrutide activates three: GIP, GLP-1 and glucagon. The added glucagon activity may raise energy use and affect liver fat. Ozempic is FDA-approved for specific uses in adults with type 2 diabetes. Retatrutide is still investigational and has no approved use.

Can you take eloralintide and retatrutide together?

No study has tested them together, so there is no safety or dosing data for the pair. Both slow stomach emptying and cause GI effects, so combined effects are unknown. Lilly's combination trials pair eloralintide with tirzepatide instead. Neither drug is available outside clinical trials.

Is retatrutide available to buy?

No. Retatrutide is not FDA-approved, and Lilly states it is legally available only to clinical trial participants. Products sold online as retatrutide are unapproved research chemicals with no verified purity or sterility. The legitimate way to access it is through a registered trial on ClinicalTrials.gov.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Start your private evaluation at TelosRX.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX